Many companies are in process of implementing big capacities..in many cases as big as mkt cap or balance sheet size...many have improving profitbitliy and Return ratios..(Dai Ichi Karkaria, Alkyl Amines, Dynemic Products looks interesting)
Disc- Invested in names mentioned.
Posts in category Value Pickr
Chemicals and Speciality Chem space in India (21-10-2015)
CCL Products (21-10-2015)
Personally found NOTHING wrong with the management interview.
He compared 1st Half'15 figures with 1st Half'16 figures and said there has been a growth in the numbers instead of a decrease which is true as well.
I don't think there is any denial mode in the management's comments. They are extremely confident about achieving their guidance numbers of 1000 cr yearly revenue (which is 20-25% growth and not a very high target).
Senior management of businesses are not sitting puppets to simply accept the biased/twisted views of the TV analysts. They can easily have the same lens of the management but would rather focus on all the negative aspects. (weak numbers, de-growth, etc)
Personally, would love to hold a big chunk of CCL in my portfolio but current valuations mean the growth story must continue for quite a few years for good returns. Waiting for it to cool down or as BM says "The stock market is a flowing river with plenty of good fish"
GRUH Finance – mini HDFC (21-10-2015)
Motilal Oswal research report dated 19 10 2015, recommends buyMotilal oswal report Gruh finance 19 10 2015.pdf (373.0 KB)
Valuation and view: GRHF has performed impressively and delivered CAGR loan
book growth of 29% between FY10 and FY15, coupled with 24% net profit growth.
The company’s presence in affordable housing segment in rural areas provides
pricing power on the asset side, with cost of funding at par with large HFCs, low C/I
ratio and impeccable asset quality expected to drive earnings growth in near to
medium term; we expect a strong 28%/25% loan growth/earnings growth for the
next three years. We marginally cut our FY16/17 estimates by 2% to factor in
higher opex and credit costs. Buy
CCL Products (21-10-2015)
There is 5cr sales which could not be realized in this quarter due to invoicing issues. So the sales would have been around 240 cr. To asses how much this contributes to PAT, and if you take into account export incentives by govt which can only be realized with sales realization, it can boost PAT upwards by ~3 cr to make PAT ~ 33 cr. May be that is the reason management is trying to justify their stand.
Torrent Pharma Ltd (21-10-2015)
Here Analysts are expecting 50mn$ for FY16 revenue. The icing on the cake is the margins which is expected 75%
Expecting more details from Concall for this quarter.
Kitex Garments Limited (21-10-2015)
Now, the other income , what exactly is this? Is this arising out of weaker rupee ? Can anyone explain please. Thanks
Torrent Pharma Ltd (21-10-2015)
Torrent's reply to the Nexium approval question posted by exchange-
STL Global Ltd. (532730) (21-10-2015)
I'm from Mumbai too. I'll try fixing up a call with the management in the coming week.
Regarding JV with the developer, do you have any idea about the deal structure? Is it revenue sharing or profit sharing or something else.
Also, if you can list some questions, from your side, to ask the managent, except regarding the project status.
I have these questions in mind:
Project Status (also status on the legal matter)
Deal structure
Revenue/profit expected and the time frame
Use of cash to be received from the project other than paying off the debt. To check if they are interested in sharing the same with minority shareholders.
Disclaimer: I have no positions currently. This shall be a high risk bet.
Torrent Pharma Ltd (21-10-2015)
dr reddy got the approval around three weeks back and couple of research reports came out which tried to quantify the sales for dr reddys.
the reports mentioned that dr reddy's can have revenue of USD40 mn in 2H FY16 and arnd USD 60mn for FY17 from nexium.